The Aegis Vaccine Platform
A New Paradigm in Cross Protective Vaccines
The Aegis Vaccine Platform offers a new paradigm in cross-protective vaccines. PGTx owns the exclusive global rights for an Aegis Salmonella-vectored vaccine for human dysenteric bacterial diseases including E. coli (ETEC,) non-typhoidal Salmonella, Shigella and Campylobacter. Aegis utilizes recombinant technology for the insertion of pathogen genes into microbial vectors. These genes are “expressed” by the vector cell to produce specific antigens and immune enhancing proteins on the cell surface. Aegis vaccines use “universal” antigens which are protective across a range of pathogen strains and even species and are manufactured using a low-cost fermentation process.
How are Aegis vaccines different from traditional vaccines?
Existing “classical” vaccines mainly offer protection against specific pathogen strains used to make the vaccines. There is often little cross protection against other strains and protection against genetic changes or mutations is minimal. Aegis vaccines offer broad spectrum cross-protection, reducing or eliminating the need for multiple vaccines, and they address the problem of mutation. Traditionally, inactivated vaccines are only effective as injectables, are labor intensive and costly to administer. Aegis vaccines can be delivered live or inactivated, and orally or intranasally.
A Novel Universal Adjuvant Delivery System
Hercules is a modified Chitosan adjuvant that enhances immune responses to multiple antigens, including orally administered antigens.
Hercules, when used orally promotes secretory immunoglobulin A (sIgA) on mucous membranes, inhibits pathogen invasion at the site of attack and is effective even with inactivated vaccines. Historically, orally delivered vaccines have tended to be live. Hercules is particularly useful in directing antigens toward antigen presenting cells.
PGTx holds the global, exclusive rights to Hercules when used in the inactivated version of the dysentery vaccine.